EP Patent

EP4233840A2 — Combinations of linagliptin and metformin

Assigned to Boehringer Ingelheim International GmbH · Expires 2023-08-30 · 3y expired

What this patent protects

The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

USPTO Abstract

The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

Drugs covered by this patent

Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim

Patent Metadata

Patent number: EP4233840A2
Jurisdiction: EP
Classification: —
Expires: 2023-08-30
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.